December 18, 2014

Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to its Clinical Advisory Board

TORONTO, ONTARIO — (December 18, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake … Continued

read
December 16, 2014

Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant

TORONTO, ONTARIO — (December 16, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. (“Stonegate”) based in Dallas, Texas. Under the terms of the agreement Stonegate will receive … Continued

read
November 28, 2014

Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results

TORONTO, ONTARIO — (November 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended September 30, 2014. Highlights for the quarter include: • The Company completed the first stage of its Phase I study, the prescheduled SAD (single ascending dose) stage, … Continued

read
November 25, 2014

Antibe Therapeutics Provides Update on its Acute Pain Drug ATB-352

TORONTO, ONTARIO — (November 25, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company’s pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits … Continued

read
October 3, 2014

Antibe Therapeutics Reports on Results of AGM Voting

TORONTO, ONTARIO — (October 3, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on October 1, 2014. The matters voted upon at the meeting and the results … Continued

read
September 15, 2014

Antibe Therapeutics Commences Trading on the US OTCQX Marketplace

TORONTO, ONTARIO — (September 15, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the OTCQX exchange under the ticker symbol “ATBPF”. Antibe’s common shares will continue to trade on the … Continued

read
September 5, 2014

Antibe Therapeutics’ Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease

TORONTO, ONTARIO — (September 5, 2014) — Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s … Continued

read
August 24, 2014

Antibe Therapeutics Reports Q1 2015 Interim Financial and Operating Results

TORONTO, ONTARIO — (August 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended June 30, 2014. Highlights for the quarter include: Conducted non-brokered private placements yielding gross proceeds of $1,244,560, which together with financings closed in fiscal Q4 2014, is … Continued

read
July 28, 2014

Antibe Therapeutics Reports Year-End Financial and Operating Results

TORONTO, ONTARIO — (July 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2014. Antibe’s highlights for the fiscal year included: Successfully closing its initial public offering and listing on the TSX Venture Exchange. Achieving … Continued

read
July 17, 2014

Antibe Therapeutics Announces the Formation of its Clinical Advisory Board

TORONTO, ONTARIO — (July 17, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce the formation of its Clinical Advisory Board with the appointment of three distinguished, internationally recognized gastroenterologists. The three appointees are: Dr. Francis Chan, Professor of Medicine at The Chinese University of Hong Kong; Dr. Angel … Continued

read
June 19, 2014

Antibe Therapeutics Receives Approval from Health Canada to Begin Human Clinical Testing

TORONTO, ONTARIO — (June 19, 2014) — Antibe Therapeutics Inc. (TSXV: ATE) is pleased to announce that it has received regulatory approval to begin its Phase I clinical trial program. Health Canada issued a ‘No Objection Letter’ in response to Antibe’s Clinical Trial Application allowing the company to initiate its study entitled ‘A Double-Blind, Placebo-Controlled, … Continued

read
May 21, 2014

Antibe Therapeutics Announces Submission of Clinical Trial Application to Health Canada for ATB-346

TORONTO, ONTARIO — (May 21, 2014) — Antibe Therapeutics Inc. (TSXV: ATE) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of … Continued

read
May 5, 2014

CEO Letter to Shareholders

To my fellow Shareholders, With our 2013-2014 fiscal year completed, I want to take a few moments to reflect on the past twelve months and to outline our plans for the year ahead. In the last year, we completed our transformation from a private, research-focused, drug-discovery venture into a publicly-traded, commercialization-focused, clinical stage drug development … Continued

read
April 28, 2014

Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $4,259,958

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has completed the third and final closing of its previously … Continued

read
April 7, 2014

Antibe Therapeutics Completes Second Closing of Non-Brokered Private Placement Bringing Total Proceeds to $3,925,358

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 7, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has completed a second closing of its previously announced non-brokered … Continued

read
April 1, 2014

Antibe Therapeutics Announces Discontinuation of Latin American Letter of Intent

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 1, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces that discussions with the potential Latin American partner with … Continued

read
March 31, 2014

Antibe Therapeutics Raises $3,015,398 in First Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 31, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has closed its previously announced non-brokered private placement raising gross … Continued

read
March 28, 2014

Antibe Therapeutics Announces Increase to Previously Announced Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce, based on increased inbound demand, that … Continued

read
March 21, 2014

Antibe Therapeutics Announces Non-Brokered Private Placement of $3,000,000

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 21, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces its intention to complete a non-brokered private placement of … Continued

read
March 17, 2014

Antibe Therapeutics Announces Completion of Pre-Clinical Program for ATB-346

TORONTO, ONTARIO — (March 17, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans. ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently … Continued

read
March 4, 2014

Antibe Therapeutics Announces Annual Compensation Changes and Grant of Stock Options

TORONTO, ONTARIO — (March 4, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that following the annual review by the Compensation Committee of the performance of the Corporation and the compensation practices of its peer companies, all personnel including Officers have been granted a 5% pay increase, and … Continued

read
January 28, 2014

Antibe Therapeutics Announces the Final Closing of its Non-Brokered Private Placement Bringing the Total Raise Under the Offering to $1.25 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (January 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that it has completed the final … Continued

read
January 24, 2014

Antibe Therapeutics Announces Increase to Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (January 24, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces an increase to the size of its non-brokered private … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK